Relapses are common in severe hematologic systemic lupus erythematosus and may be prevented by early institution of immunosuppressive agents: Α real-life single-center study

Abstract

Background

Hematologic manifestations are common in systemic lupus erythematosus (SLE), either at initial presentation or during the course of the disease, but data regarding their natural history are scarce.

Objective

To describe the characteristics, treatments, and outcomes of severe hematological manifestations in a large cohort of lupus patients.

Methods

Retrospective cohort study of patients in the “Attikon” lupus cohort who had a history of a severe hematologic manifestation, defined as autoimmune hemolytic anemia (AIHA) with hemoglobin < 8 g/dL, thrombocytopenia with platelet count < 30,000/mm³, Evans syndrome with hemoglobin < 8 g/dL, and/or platelet count < 30,000/mm³, neutropenia with < 500 neutrophils/mm³, thrombotic microangiopathy (TMA)/thrombotic thrombocytopenic purpura (TTP)-like syndrome, or macrophage activation syndrome (MAS). Demographic and clinical characteristics, treatments, and outcomes were recorded.

Results

From over 300 patients with hematologic manifestations, 41 qualified as severe (70.7% women, mean [SD] age at SLE diagnosis 42.6 [18.0] years). Hematologic manifestations preceded SLE diagnosis in 13 patients (31.7%), was concomitant to SLE diagnosis in 16 patients (39%), and occurred during the course of the disease in 12 (29.3%) patients, with a mean (SD) disease duration of 8.7 (5.5) years. Thrombocytopenia was the most common severe hematological manifestation (56.1%), followed by AIHA (17.1%) and TTP-like syndrome (12.2%). For initial treatment, all patients were treated with glucocorticoids (GC), while rituximab and cyclophosphamide were the most frequently used immunosuppressive agents. Following initial treatment, relapse occurred in 22 patients (53.7%). Compared to patients that did not relapse, those that relapsed had less often received concomitant immunosuppressive agents following treatment of initial episode (n = 17/23, 73.9% vs 5/17, 29.4%, p = 0.005).

Conclusion

Severe hematologic disease in SLE has a high risk of relapse, which may be mitigated by the early institution of GC-sparing agents.

Keywords

haematologic changes systemic lupus erythematosus treatment

Get full access to this article

View all access options for this article.

References

Fayyaz

Igoe

Kurien

, et al. Haematological manifestations of lupus. Lupus Sci Med 2015; 2(1): e000078.

Hepburn

Narat

Mason

. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology (Oxford) 2010; 49(12): 2243–2254.

Nossent

Swaak

. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Q J Med 1991; 80(291): 605–612.

Zhu

F-X

Huang

J-Y

, et al. Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study. Ann Rheum Dis 2020; 79: 772–779.

Liebman

Weitz

. Autoimmune hemolytic anemia. Med Clin North Am 2017; 101(2): 351–359.

Gavand

P-E

Serio

Arnaud

, et al. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 103 episodes in 89 adult patients. Autoimmun Rev 2017; 16: 743–749.

Fanouriakis

Tziolos

Bertsias

, et al. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 2021; 80(1): 14–25.

Miranda-Hernández

Cruz-Reyes

Monsebaiz-Mora

, et al. Active haematological manifestations of systemic lupus erythematosus lupus are associated with a high rate of in-hospital mortality. Lupus 2017; 26(6): 640–645.

Jung

J-H

Soh

M-S

Ahn

Y-H

, et al. Thrombocytopenia in systemic lupus erythematosus: clinical manifestations, treatment, and prognosis in 230 patients. Medicine 2016; 95: e2818.

10.

Fanouriakis

Kostopoulou

Alunno

, et al. Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019; 78(6): 736–745.

11.

Khellaf

Michel

Schaeffer

, et al. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica 2005; 90(6): 829–832.

12.

Nikolopoulos

Kostopoulou

Pieta

, et al. Evolving phenotype of systemic lupus erythematosus in caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the ‘Attikon’ cohort. Lupus 2020; 29(5): 514–522.

13.

Hochberg

. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40(9): 1725.

14.

Petri

Orbai

Alarcón

, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64(8): 2677–2686.

15.

Aringer

Costenbader

Daikh

, et al. European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019; 71(9): 1400–1412.

16.

Bradbury

Pell

Hill

, et al. Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. N Engl J Med 2021; 385(10): 885–895.

17.

Goebel

Gassel

Goebel

. Evaluation of azathioprine in autoimmune thrombocytopenia and lupus erythematosus. Scand J Haematol 1973; 10: 28–34.

18.

Quartuccio

Sacco

Franzolini

, et al. Efficacy of cyclosporin-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus. Lupus 2006; 15: 76–79.

19.

Boumpas

Barez

Klippel

, et al. Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 1990; 112: 674–677.

20.

Serris

Amoura

Canouï-Poitrine

, et al. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults. Am J Hematol 2018; 93(3): 424–429.

21.

Thai

Le Gallou

Robbins

, et al. BAFF and CD4+ T cells are major survival factors for long-lived splenic plasma cells in a B-cell-depletion context. Blood 2018; 131(14): 1545–1555.

22.

Mahévas

Azzaoui

Crickx

, et al. Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial. Haematologica 2021; 106(9): 2449–2457.

23.

Ostendorf

Burns

Durek

, et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med 2020; 383(12): 1149–1155.

24.

Karageorgas

Zomas

Kazakou

, et al. Successful treatment of life-threatening autoimmune haemolytic anaemia with ofatumumab in a patient with systemic lupus erythematosus. Rheumatology (Oxford) 2016; 55(11): 2085–2087.